Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ Germany · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Oct 2026: B. Braun said it will close its US unit B. Braun Interventional Systems, with sales continuing to 31 Mar 2027, to streamline operations; it reported no immediate supply disruption and said its global interventional vascular business is unaffected.
No data breaches, cyber incidents or regulator action involving B. Braun found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Jan 2026: B. Braun Medical Inc. began a Class 2 US recall of one lot of a spinal epidural catheter kit after its supplier recalled the liquid adhesive included in the kit, whose tubing may crack and make it unusable.
No notable go-lives, troubled implementations, terminations or customer disputes involving B. Braun found in HSH's search of the last 24 months.
No competitors linked yet.